Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2023 Earnings Call Transcript February 7, 2024 Neurocrine Biosciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and welcome to Neurocrine Biosciences’ year-end and fourth quarter results call. At this time, all […]
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2023 Earnings Call Transcript October 31, 2023 Operator: Good day, everyone. And welcome to the Neurocrine Biosciences Reports third quarter results. At this time, all participants are in a listen-only mode. Later you will have the opportunity to ask questions during the question-and-answer session. [Operator Instructions] Please note this call […]
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2023 Earnings Call Transcript August 1, 2023 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS is $-0.18 EPS, expectations were $0.77. Operator: Good day, everyone, and welcome to today’s Neurocrine Biosciences Reports Second Quarter Results. [Operator Instructions] It is now my pleasure to turn today’s program over to Todd […]
Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) had its target price cut by Barclays from $131.00 to $125.00 in a research note issued to investors on Thursday, The Fly reports. Several other research analysts have also recently issued reports on NBIX. StockNews.com initiated coverage on Neurocrine Biosciences in a report on Thursday, March 16th. They issued […]
Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) had its target price decreased by Mizuho from $116.00 to $111.00 in a research note released on Thursday, The Fly reports. Other research analysts also recently issued reports about the company. Evercore ISI upgraded Neurocrine Biosciences from an in-line rating to an outperform rating and set a $130.00 target […]